Sarasin & Partners LLP Buys Shares of 14,200 GE HealthCare Technologies Inc. $GEHC

Sarasin & Partners LLP purchased a new stake in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 14,200 shares of the company’s stock, valued at approximately $909,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Laurel Wealth Advisors LLC bought a new position in GE HealthCare Technologies in the 4th quarter valued at $26,000. Optima Capital LLC purchased a new stake in shares of GE HealthCare Technologies in the fourth quarter worth $27,000. Godfrey Financial Associates Inc. bought a new stake in GE HealthCare Technologies during the fourth quarter valued at $27,000. Montag A & Associates Inc. grew its position in GE HealthCare Technologies by 105.4% during the fourth quarter. Montag A & Associates Inc. now owns 341 shares of the company’s stock worth $28,000 after buying an additional 175 shares in the last quarter. Finally, Transamerica Financial Advisors LLC grew its position in GE HealthCare Technologies by 331.6% during the fourth quarter. Transamerica Financial Advisors LLC now owns 341 shares of the company’s stock worth $28,000 after buying an additional 262 shares in the last quarter. 82.06% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

GEHC has been the topic of several recent analyst reports. Hovde Group began coverage on GE HealthCare Technologies in a report on Friday, July 17th. They issued a “market perform” rating and a $14.00 price target on the stock. Royal Bank Of Canada started coverage on shares of GE HealthCare Technologies in a research report on Tuesday, June 23rd. They issued an “outperform” rating and a $80.00 price objective on the stock. Jefferies Financial Group dropped their target price on shares of GE HealthCare Technologies from $105.00 to $90.00 in a research report on Thursday, April 30th. UBS Group increased their price target on shares of GE HealthCare Technologies from $67.00 to $73.00 and gave the stock a “neutral” rating in a report on Friday, July 31st. Finally, Evercore reiterated an “outperform” rating and issued a $84.00 target price on shares of GE HealthCare Technologies in a research report on Thursday, July 30th. Ten equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, GE HealthCare Technologies presently has a consensus rating of “Hold” and an average price target of $77.73.

GE HealthCare Technologies Stock Up 0.1%

Shares of NASDAQ GEHC opened at $70.31 on Friday. GE HealthCare Technologies Inc. has a one year low of $58.75 and a one year high of $89.77. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.26 and a quick ratio of 0.97. The firm’s 50 day simple moving average is $64.53 and its two-hundred day simple moving average is $70.06. The stock has a market capitalization of $31.76 billion, a P/E ratio of 16.13, a PEG ratio of 2.03 and a beta of 0.69.

GE HealthCare Technologies (NASDAQ:GEHC) last announced its quarterly earnings data on Wednesday, July 29th. The company reported $1.13 earnings per share for the quarter, topping analysts’ consensus estimates of $1.04 by $0.09. GE HealthCare Technologies had a net margin of 9.33% and a return on equity of 20.12%. The firm had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.26 billion. During the same period in the previous year, the business posted $1.06 EPS. The business’s quarterly revenue was up 5.8% on a year-over-year basis. As a group, analysts expect that GE HealthCare Technologies Inc. will post 4.93 EPS for the current fiscal year.

GE HealthCare Technologies Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Friday, July 24th will be paid a $0.035 dividend. This represents a $0.14 dividend on an annualized basis and a dividend yield of 0.2%. The ex-dividend date of this dividend is Friday, July 24th. GE HealthCare Technologies’s payout ratio is 3.21%.

Insider Buying and Selling

In other news, Director Kevin Lobo acquired 10,000 shares of the firm’s stock in a transaction on Friday, May 22nd. The shares were purchased at an average price of $64.18 per share, for a total transaction of $641,800.00. Following the completion of the transaction, the director owned 14,363 shares of the company’s stock, valued at $921,817.34. The trade was a 229.20% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Rodney F. Hochman bought 1,618 shares of the company’s stock in a transaction dated Tuesday, May 12th. The shares were purchased at an average price of $62.03 per share, with a total value of $100,364.54. Following the completion of the acquisition, the director owned 1,618 shares of the company’s stock, valued at $100,364.54. This trade represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. 0.36% of the stock is owned by insiders.

GE HealthCare Technologies Profile

GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.